CBLLCBLLNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot

CeriBell (NASDAQ: CBLL) executives outlined the company's 2026 priorities and growth drivers during a fireside chat at the 46th annual TD Cowen Healthcare Conference, emphasizing continued expansion in hospital adoption, upcoming pediatric and neonatal offerings, early plans for a delirium commercialization pilot, and efforts to maintain strong gross margins amid shifting tariff dynamics. 2026 outlook and

defenseworld.net

CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium

CeriBell (NASDAQ: CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told investors the company ended 2025 with $89 million in revenue, representing 36% year-over-year growth, and

defenseworld.net

Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Target Price at $24.67

Shares of CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the

defenseworld.net

Allurion Technologies (NYSE:ALUR) & CeriBell (NASDAQ:CBLL) Head-To-Head Survey

CeriBell (NASDAQ: CBLL - Get Free Report) and Allurion Technologies (NYSE: ALUR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Recommendations This is a breakdown of recent

defenseworld.net

Analyzing CeriBell (NASDAQ:CBLL) & Nephros (NASDAQ:NEPH)

CeriBell (NASDAQ: CBLL - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings. Insider and Institutional Ownership 41.1% of Nephros shares are

seekingalpha.com

CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript

zacks.com

CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.

globenewswire.com

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

globenewswire.com

Ceribell to Participate in Upcoming March Investor Conferences

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:50 a.m. Pacific Standard Time / 1:50 p.m. Eastern Standard Time.

globenewswire.com

Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.

gurufocus.com

Chuck Royce's Strategic Moves: Significant Reduction in Haemonetics Corp

Exploring the Fourth Quarter 2025 13F Filing Chuck Royce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh

defenseworld.net

CeriBell, Inc. (NASDAQ:CBLL) Receives $24.67 Average Price Target from Analysts

CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company.

defenseworld.net

CeriBell (NASDAQ:CBLL) Director Josef Parvizi Sells 25,000 Shares of Stock

CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) Director Josef Parvizi sold 25,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.94, for a total transaction of $573,500.00. Following the completion of the transaction, the director directly owned 747,652 shares in the company, valued

defenseworld.net

CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion

CeriBell (NASDAQ: CBLL) outlined its recent progress and 2026 priorities at a JPMorgan MedTech event, emphasizing continued growth in acute-care seizure detection and an expanding roadmap for additional EEG-based indications, including delirium and stroke monitoring. Platform overview and 2025 accomplishments Chief Executive Officer Jane Chao said the company has built a neuromonitoring platform designed to make

seekingalpha.com

CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

defenseworld.net

Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) CEO Xingjuan Chao sold 79,000 shares of the firm's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the transaction, the chief executive officer directly owned 741,248 shares in

zacks.com

CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection

Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.

globenewswire.com

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting.

globenewswire.com

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.

defenseworld.net

CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 36,000 Shares of Stock

CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) CFO Scott Blumberg sold 36,000 shares of the company's stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00. Following the sale, the chief financial officer owned 118,842 shares in the company,

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance